| Autor: |
Parker, H., Rose-Zerilli, M.J.J., Larrayoz, M., Clifford, R., Edelmann, J., Blakemore, S., Gibson, J., Wang, J., Ljungström, V., Wojdacz, T.K., Chaplin, T., Roghanian, A., Davis, Z., Parker, A., Tausch, E., Ntoufa, S., Ramos, S., Robbe, P., Alsolami, R., Steele, A.J., Packham, G., Rodriquez-Vicente, A.E., Brown, L., McNicholl, F., Forconi, F., Pettitt, A., Hillmen, P., Dyer, M., Cragg, M.S., Chelala, C., Oakes, C.C., Rosenquist, R., Stamatopoulos, K., Stilgenbauer, S., Knight, S., Schuh, A., Oscier, D.G., Strefford, J.C. |
| Jazyk: |
angličtina |
| Rok vydání: |
2016 |
| Popis: |
Histone methyltransferases (HMTs) are important epigenetic regulators of gene transcription and are disrupted at the genomic level in a spectrum of human tumors including haematological malignancies. Using high-resolution SNP-arrays, we identified recurrent deletions of the SETD2 locus in 3% (8/261) of chronic lymphocytic leukemia (CLL) patients. Further validation in two independent cohorts showed that SETD2 deletions were associated with loss of TP53, genomic complexity and chromothripsis. With next generation sequencing we detected mutations of SETD2 in an additional 3.8% of patients (23/602). In most cases, SETD2-deletions or mutations were often observed as a 56 clonal event and always as a mono-allelic lesion, leading to reduced mRNA expression in SETD2-disrupted cases. Patients with SETD2 abnormalities and wild-type TP53 and ATM from five clinical trials employing chemotherapy or chemo-immunotherapy, had reduced progression-free and overall survival compared to cases wild-type for all three genes. Consistent with its postulated role as a tumor suppressor, our data highlights SETD2 aberration as a recurrent, early loss-of-function event in CLL pathobiology linked to aggressive disease. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
